Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07455617) titled 'Study of ABO2102 in KRAS-Mutated Solid Tumors' on Feb. 25.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Suzhou Abogen Biosciences Co., Ltd.

Condition: Advanced / Metastatic Solid Tumor

Intervention: Drug: ABO2102 Injection

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: February 2026

Target Sample Size: 101

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07455617

Published by HT Digital Content ...